DUOS, the digital health innovator empowering older adults to live independently, is proud to announce the launch of Chat 2.0 and will showcase the new features at this year’s HLTH 2024 Conference.

The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with advanced Parkinson’s disease. This novel treatment is the first of its ...

Equipped with sophisticated jamming pods and advanced electronic systems, the Growler can neutralize threats without firing a single weapon, allowing strike aircraft to safely penetrate enemy ...

Emcyte Pure Two Emcyte Sapphire Series Centrifuge Introducing the latest in PRP technology—PRP Labs offers Emcyte Kits for superior platelet recovery and the Sapphire Series Centrifuge for precision p ...

Advanced Micro Devices has emerged as a worthy competitor and is attracting many of Nvidia's top customers. AMD CEO Lisa Su just gave investors a fresh look at the company's newest AI chips.

NORTH CHICAGO, IL, USA I October 17, 2024 I AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved VYALEV™ (foscarbidopa and foslevodopa) as the first and ...

AbbVie has finally won Food and Drug Administration approval of its Vyalev therapy for patients with advanced ... the treatment of motor fluctuations in adults with the neurodegenerative condition.

AbbVie Inc. said Thursday the Food and Drug Administration has approved its vyalev as the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of ...

The approval was supported by the pivotal Phase 3, 12-week study evaluating the efficacy of continuous subcutaneous infusion of VYALEV in adult patients with advanced PD compared to oral immediate ...

Oct. 17, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved VYALEV™ (foscarbidopa and foslevodopa) as the first and only ...